Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
BRG1-IN-1
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "BRG1-IN-1" in MCE Product Catalog:
3
Research Areas:
FHD-286 is a selective, oral inhibitor of SMARCA4/SMARCA2 ATPase (BRG1 and BRM) inhibitor. FHD-286 has the potential for the research of BAF (BRG1/BRM-associated factor)-related disorders such as acute myeloid leukemia .
2
2 Cited Publications
Target:
Research Areas:
FHT-1015 is a selective SMARCA4 (IC50 = 4 nM) and SMARCA2 (IC50 = 5 nM) (also known as BRG1 and BRM) inhibitor. FH-1015 is an allosteric inhibitor that causes conformation change in the BRG1/BRM protein upon interaction with an allosteric site, inhibiting ATPase activity. FH-1015 interferes with tumor cell growth and migration. FH-1015 can be studied in research for uveal melanoma and hematologic cancer .
Target:
Research Areas:
BRM/BRG1 ATP Inhibitor-2 is a BRG1/BRM ATPase inhibitor for the research of BAF-related disorders.
Cat. No.: HY-168242
CAS No.: 2724268-88-4
Target:
Research Areas:
PROTAC BRM/BRG1 degrader-1 (Example 253) is a PROTAC BRM/BRG1 degrader, with DC50 of 10-100 nM for BRM, > 1 μM for BRG1. PROTAC BRM/BRG1 degrader-1 can be used for cancer research .
Cat. No.: HY-148374
CAS No.: 2422030-94-0
Target:
Research Areas:
BRM/BRG1 ATP Inhibitor-4 is a BRG1/BRM inhibitor. BRM/BRG1 ATP Inhibitor-4 can be used for the research of cancers and BAF complex-related disorders .
Cat. No.: HY-161886
CAS No.: 2270879-43-9
Target:
Research Areas:
SMARCA2-IN-7 (compound 12), a dual inhibitor of BRM and BRG1 (IC50 < 0.005 for both), has an anti-tumor proliferation effect that inhibits BRG1-deleted SKMEL5 tumor proliferation with a cell proliferation activity AAC50 of 13 nM in SKMEL5. The cell proliferation activity AAC50 of KRT880 in H1299 cells was 42 nM .
Cat. No.: HY-161885
CAS No.: 2270875-79-9
Target:
Research Areas:
SMARCA2-IN-6 is a SMARCA2 and SMARCA4 inhibitor, with an IC50 value of <0.005 μM for both SMARCA2 and SMARCA4. SMARCA2-IN-6 exerts anticancer activity against BRG1-mutant melanoma. SMARCA2-IN-6 can be used for research related to Brg1/Smarca4-mutant cancers .
Cat. No.: HY-W539427
CAS No.: 1893977-70-2
Research Areas:
BRM/BRG1 ligand 1 is a BRM/BRG1 ligand, and can be used for synthesis of PROTAC BRM/BRG1 degrader-1 (HY-168242) .
Cat. No.: HY-178490
CAS No.: 2468046-72-0
Target:
Research Areas:
BRM/BRG1 ATP-IN-8 (Compound Cpd14) is an orally active BRG1/BRM ATPase domain inhibitor. BRM/BRG1 ATP-IN-8 exerts antitumor effects by disrupting aberrant chromatin remodeling in cancer cells, inducing apoptosis and growth arrest. BRM/BRG1 ATP-IN-8 is promising for research of BRG1/BRM-dependent malignancies, including hematological cancers, prostate cancer, breast cancer, and Ewing's sarcoma .
Cat. No.: HY-168243
CAS No.: 3031995-12-4
Target:
Research Areas:
E3 ligase Ligand 36 is an E3 ligase Ligand, and can be used for synthesis of PROTACs, such as PROTAC BRM/BRG1 degrader-1 (HY-168242) .
Cat. No.: HY-168244
Target:
Research Areas:
TsO-C2-Piperidine-O-azetidine-CO-Ph-C2-OH is a PROTAC linker, and can be used for PROTAC synthesis, such as PROTAC BRM/BRG1 degrader-1 (HY-168242) .
Cat. No.: HY-148373
CAS No.: 2368901-31-7
Target:
Research Areas:
BRM/BRG1 ATP Inhibitor-3 is a BRG1/BRM inhibitor. BRM/BRG1 ATP Inhibitor-3 inhibits BRM and BRG1 with IC50 values of 10.4 nM and 19.3 nM, respectively. BRM/BRG1 ATP Inhibitor-3 can be used for the research of cancers and BAF complex-related disorders .
Cat. No.: HY-178481
CAS No.: 2468046-57-1
Target:
Research Areas:
BRM/BRG1 ATP-IN-5 (Compound 6) is a BRG1/BRM inhibitor. BRM/BRG1 ATP-IN-5 acts on the BAF complex, which is involved in chromatin regulation and gene expression via ATP-dependent chromatin remodeling. BRM/BRG1 ATP-IN-5 demonstrates anti-tumor potential, particularly in cancers associated with BAF complex disorders .
Cat. No.: HY-178484
CAS No.: 2468049-60-5
Target:
Research Areas:
BRM/BRG1 ATP-IN-6 (Compound 105) is a BRG1/BRM inhibitor. BRM/BRG1 ATP-IN-6 acts on the BAF complex, which is involved in chromatin regulation and gene expression via ATP-dependent chromatin remodeling. BRM/BRG1 ATP-IN-6 demonstrates anti-tumor potential, particularly in cancers associated with BAF complex disorders .
Cat. No.: HY-168245
Research Areas:
E3 Ligase Ligand-linker Conjugate 126 is an E3 Ligase Ligand-linker Conjugate, and can be used for synthesis of PROTACs, such as PROTAC BRM/BRG1 degrader-1 (HY-168242) .
Cat. No.: HY-144835R
CAS No.: 2671128-05-3
Synonyms: FHD-286 (Standard)
Research Areas:
Camibirstat (Standard) is the analytical standard of Camibirstat (HY-144835). This product is intended for research and analytical applications. FHD-286 is a selective, oral inhibitor of SMARCA4/SMARCA2 ATPase (BRG1 and BRM) inhibitor. FHD-286 has the potential for the research of BAF (BRG1/BRM-associated factor)-related disorders such as acute myeloid leukemia .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
